Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-28
2008-03-25
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
07348325
ABSTRACT:
In general, the instant invention comprises compounds having Formulae I and II:including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
REFERENCES:
patent: 5646176 (1997-07-01), Golik et al.
patent: 6214344 (2001-04-01), Schwall et al.
patent: 6262094 (2001-07-01), Hoefle et al.
patent: 6750246 (2004-06-01), Kadow et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 2003/0186982 (2003-10-01), Godfrey Jr. et al.
patent: WO99/02514 (1999-01-01), None
patent: WO00/71129 (2000-11-01), None
patent: WO02/40486 (2002-05-01), None
patent: WO03/042172 (2003-05-01), None
patent: WO03/090912 (2003-11-01), None
patent: WO03/091229 (2003-11-01), None
patent: WO2004/054514 (2004-07-01), None
patent: WO2006/004636 (2006-01-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Corso et al., Trends in Molecular Medicine, 11(6), 284-292, 2005.
Kermogrant et al., Cell Cycle 4(3), 352-355, 2005.
Bardelli, A. et al., “Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required forMET-mediated metastasis”, Oncogene, vol. 18, pp. 1139-1146 (1999).
Bottaro, D.P. et al., “Identification of Hepatocyte Growth Factor receptor as thec-metProto-Oncogene Product”, Science, vol. 251, pp. 802-804 (1991).
Bussolino, F. et al., “Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth”, The J. of Cell Biology, vol. 119(3), pp. 629-641 (1992).
Camp, R.L. et al., “Metexpression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma”, Cancer, vol. 86(11), pp. 2259-2265 (2000).
Cañibano, V. et al., “Mild regioselective Halogenation of Activated Pyridines withN-Bromosuccinimide”, Synthesis, vol. 14, pp. 2175-2179 (2001).
Christensen, J. G. et al., “A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo”, Cancer Research, vol. 63, pp. 7345-7355 (2003).
Cooper, C.S. et al., “Amplification and overexpression of themetgene in spontaneously transformed NIH3T3 mouse fibroblasts”, The EMBO Journal, vol. 5(10), pp. 2623-2628 (1986).
Di Renzo, M. et al., “Overexpression and Amplification of the Met/HGF Receptor Gene during the Progression of Colorectal Cancer1”, Clinical Cancer Research, vol. 1, pp. 147-154 (1995).
Furge, K. et al., “Met receptor tyrosine kinase: enhanced signaling through adapter proteins”, Oncogene, vol. 19, pp. 5582-5589 (2000).
Greene, T., “Protective Groups in Organic Synthesis”, Wiley & Sons, Inc. (1991).
Gual, P. et al., “Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis”, Oncogene, vol. 19, pp. 1509-1518 (2000).
Hunt, J.T. et al., “Discovery of the Pyrrolo [2,1-f] [1,2,4] triazine Nucleus as a New Kinase Inhibitor Template”, J. Med. Chem., vol. 47, pp. 4054-4059 (2004).
Jiang, W.G. et al., “Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET1” Clinical Cancer Research, vol. 9, pp. 4274-4281 (2003).
Kenworthy, P. et al., “The presence of scatter factor in patients with metastatic spread to the pleura”, Br. J. Cancer, vol. 66, pp. 243-247 (1992).
Lai, Jui-Fen et al., “Involvement of Focal Adhesion Kinase in Hepatocyte Growth Factor-induced Scatter of Madin-Darby Canine Kidney Cells*”, The J. of Biological Chemistry, vol. 275(11), pp. 7474-7480 (2000).
Lee, Jae-Ho et al., “A novel germ line juxtamembraneMetmutation in human gastric cancer”, Oncogene, vol. 19, pp. 4947-4953 (2000).
Lubensky, I. et al., “Hereditary and Sporadic Papillary Renal Carcinomas with c-metMutations Share a Distinct Morphological Phenotype”, American J. of Pathology, vol. 155(2), pp. 517-526 (1999).
Masuya, D. et al., “The tumor-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumor growth and prognosis in non-small-cell lung cancer patients”, British J. of Cancer, vol. 90, pp. 1555-1562 (2004).
Matsumoto, K. et al., “Hepatocyte Growth Factor: Molecular Structure, Roles in Liver Regeneration, and Other Biological Functions”, Critical Reviews in Oncogenesis, vol. 31(1,2) pp. 27-54 (1992).
Montesano. R. et al., “Identification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor”, Cell, vol. 67, pp. 901-908 (1991).
Park M. et al., “Sequence ofMETprotooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors”, Proc. Natl. Acad. Sci., vol. 84, pp. 6379-6383 (1987).
Rong, S. et al., “Met Proto-oncogene Product is Overexpressed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients1”, Cancer Research, vol. 55, pp. 1963-1970 (1995).
Rong, S. et al., “Met Expression and Sarcoma Tumorigenicity”, Cancer Research, vol. 53, pp. 5355-5360 (1993).
Sachs, M. et al., “Essential Role of Gab1 for Signaling by the c-Met Receptor In Vivo”, The J. of Cell Biology, vol. 150(6), pp. 1375-1384 (2000).
Scarpino, S. et al., “Hepatocyte Growth Factor (HGF) Stimulates Tumour Invasiveness in Papillary Carcinoma of the Thyroid”, J. of Pathology, vol. 189, pp. 570-575 (1999).
Schaeper, U. et al., “Coupling of Gab1 to c-Met, Grb2, and Shp2 Mediates Biological Responses”, The J. of Cell Biology, vol. 149(7), pp. 1419-1432 (2000).
Soman, N. et al., “TheTPR-METoncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions”, PNAS, vol. 88, pp. 4892-4896 (1991).
Sonnenberg, E. et al., “Scatter Factor/Hepatocyte Growth Factor and Its Receptor, the c-met Tyrosine Kinase, Can Mediate a Signal Exchange between Mesenchyme and Epithelia during Mouse Development”, The J. of Cell Biology, vol. 123(1), pp. 223-235 (1993).
Stabile, L.P. et al., “Inhibition of human non-small cell lung tumors by a c-Met Antisense/U6 expression plasmid strategy” Gene Therapy, vol. 11, pp. 3325-3335 (2004).
Stella, M.C. et al., “HGF: a multifunctional growth factor controlling cell scattering”, International J. of Biochemistry & Cell Biology, vol. 31, pp. 1357-1362 (1999).
Stoker, M. et al., “Scatter factor is a fibroblast-derived modulator of epithelial cell mobility”, Nature, vol. 327, pp. 239-242 (1987).
Stuart, K. et al., “Hepatocyte growth factor/scatter factor-induced intracellular signalling”, Int. J. Exp. Path., vol. 81, pp. 17-30 (2000).
Takayama, H. et al., “Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor”, PNAS, vol. 94, pp. 701-706 (1997).
Tanimura, S. et al., “Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering”, Oncogene, vol. 17, pp. 57-65 (1998).
Thibault, C. et al., “Concise and Efficient Synthesis of 4-Fluoro-1H-pyrrolo[2,3-b] pyridine”, Organic Letters, vol. 5(26), pp. 5023-5025 (2003).
Borzilleri Robert M.
Cai Zhen-Wei
Kim Kyoung S.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Duncan Sammy G.
Gibbons Maureen S.
LandOfFree
Pyrrolotriazine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolotriazine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967210